Orforglipron sleep apnea trial ATTAIN OSA set for Monday AHA late breaker in Chicago

CHICAGO. Results from the orforglipron sleep apnea trial known as ATTAIN-OSA are scheduled for a late breaking session on Monday morning, Nov. 9, at the American Heart Association meeting, according to a MedPage Today preview. The placebo controlled Phase 3 program tests Eli Lilly's once daily oral GLP 1 receptor agonist, sold as Foundayo, in adults who have both obstructive sleep apnea and excess weight. The preview gave no efficacy figures. The readout will show whether the pill changes how often breathing stops or becomes shallow during sleep after 52 weeks.

ATTAIN OSA sits among the AHA late breakers

Main presentations at the AHA Scientific Sessions opened on Saturday, Nov. 7, and close on Monday, Nov. 9, while extra programming started a day earlier, according to the MedPage Today preview. Attendees meet in Chicago, and some sessions also stream online. MedPage Today listed innovations tied to GLP 1 drugs among the topics that must still make their case this year, alongside older pillars of heart care such as intensive blood pressure control and statins. The orforglipron sleep apnea trial is the only GLP 1 late breaker the preview named. It sits in the Monday morning slot, after two days of trials on blood pressure targets, statin withdrawal, inflammation and lipoprotein(a). No company statement on the timing was included in the preview, and Lilly has not been quoted on what the data show.

The table below lists the late breakers the preview highlighted, with the day each one is due. Two of them, ZEUS for the interleukin 6 blocker ziltivekimab and Lp(a)HORIZON for the lipoprotein(a) lowering drug pelacarsen, already had disappointing topline results in public for months, MedPage Today said. Both were still chosen for the opening late breaking session. The SUPERIOR trial tests sacubitril/valsartan (Entresto) for preventing atrial fibrillation from coming back after catheter ablation in people with hypertension. The OPTIMAL trials test a systolic target below 120 mmHg in stroke survivors and in people with type 2 diabetes, two groups the SPRINT trial left out. WATCH-LV, the closing late breaker, tests smartwatches with AI enabled ECGs as a check on left ventricular systolic function.

What ATTAIN OSA measures in obstructive sleep apnea

ATTAIN-OSA groups two Phase 3 studies under one master protocol, and each is randomized, double blind, run at many centers and compared with placebo, according to the published design paper. Study 1 enrolls adults with moderate to severe obstructive sleep apnea who cannot or will not use positive airway pressure, the mask therapy known as PAP. Study 2 enrolls PAP users, who stop the device for a set washout period before their baseline overnight sleep study. The trial registry entry lists a screening apnea hypopnea index of at least 15 events per hour as an entry rule. It excludes people with past airway surgery for sleep apnea, people whose apneas are mostly central or mixed, and people using a device other than PAP. Eli Lilly is the sponsor, the registry shows.

The main result is the change in the apnea hypopnea index from baseline to week 52, measured against placebo.

The main result is the change in the apnea hypopnea index from baseline to week 52, measured against placebo. That index counts how often breathing stops or turns shallow per hour of sleep. Key secondary measures include sleep apnea specific hypoxic burden, a score of how much oxygen drops during these events, plus a patient reported sleep impairment scale, high sensitivity C reactive protein and body weight, the design paper says. The authors said they chose hypoxic burden because it predicts major cardiovascular outcomes linked to sleep apnea. Participants take one capsule of drug or matching placebo each day. Each person moves up in small steps to the highest amount they tolerate, the paper states. Peptide Zone does not report the study amounts, because sleep apnea is not an approved use.

Why a non peptide GLP 1 receptor agonist matters here

Orforglipron is not a peptide. A UK NIHR health technology briefing from October 2025 describes it as a selective small molecule, non peptide drug that activates the GLP 1 receptor, the target of the natural peptide hormone. That briefing listed an estimated 600 participants for ATTAIN-OSA. Peptide Zone covered the gap between the non peptide pill and injectable peptides when its first Phase 3 obesity result came out. For the orforglipron sleep apnea trial, the design paper frames the question around access. Its authors ask whether a once daily oral drug can offer an effective and more accessible way to treat moderate to severe obstructive sleep apnea in adults with excess weight. The trial does not compare orforglipron with any injectable drug, so it cannot answer which works better.

Lilly already sells orforglipron in the US under the Foundayo brand, as our report on Foundayo on telehealth describes. A sleep apnea result on Monday would not change what the drug is approved for. Any new use would need a filing and a review by regulators such as the FDA, and the preview did not say whether or when Lilly plans to file. Doctors can prescribe approved drugs off label, but trial data in one condition do not make a drug proven in another. People with sleep apnea should not start or change a GLP 1 drug based on a conference talk. Treatment choices belong with a clinician who knows the full record and the person's own risks.

What the Monday readout can and cannot show

Several things are not known before the session. The preview gave no apnea hypopnea index change, no weight loss figure, no side effect rates and no dropout numbers. It also did not say whether the two studies will be shown together or one at a time. The design paper names one limit in plain terms: ATTAIN-OSA does not address whether the treatment effects last over the long term. Fifty two weeks is the full span of the main result. Readers should look for the size of the drop against placebo, how many people stopped the drug because of side effects, and whether results differ between PAP users and non users. Any results from the orforglipron sleep apnea trial at AHA will be an early public look, and a full peer reviewed paper may follow later.

The cardiology setting raises a separate question about heart risk. ATTAIN-OSA was not built to count heart attacks, strokes or deaths. It measures sleep breathing, oxygen burden, an inflammation marker and weight. A fall in hypoxic burden or C reactive protein would be a signal worth tracking, not proof of fewer cardiac events. Our earlier report on heart failure pressure readings covered a small retrospective study of other drugs in this class, a weaker kind of evidence than a randomized trial. Peptide Zone will report the numbers when Lilly or the investigators release them on Monday. Until then, the key fact is the date and the design: a 52 week, placebo controlled Phase 3 test in two groups of adults with moderate to severe disease.

Conclusion

The orforglipron sleep apnea trial reaches the AHA stage on Monday, Nov. 9, with no efficacy data public beforehand. ATTAIN-OSA tests a once daily non peptide pill against placebo over 52 weeks in adults with moderate to severe obstructive sleep apnea and excess weight, with and without PAP. The main measure is breathing events per hour of sleep. Long term durability and heart outcomes sit outside its design. Approval for a new use would still need regulators to review the full data. This report is for research context only and is not medical advice.